Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III study of PTI-428, PTI-808 and PTI-801 combination

Next Previous
Trial Profile

A Phase III study of PTI-428, PTI-808 and PTI-801 combination

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dirocaftor (Primary) ; Nesolicaftor (Primary) ; Posenacaftor (Primary) ; PTI NC 733 (Primary)
  • Indications Cystic fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms MORE
  • Sponsors Kineta; Proteostasis Therapeutics; Yumanity Therapeutics

    • Most Recent Events

    • 19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
    • 13 Jan 2020 According to a Proteostasis Therapeutics media release, the company completed a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK
    • 17 Dec 2019 According to a Proteostasis Therapeutics media release, this trial is expected to begin in 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top